Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PRNP | P04156 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16503510 | 1.00 | TSHR (0.44) | TSHRMEN1KMT2AMAPTHTT | |
| SCHEMBL16263403 | 0.86 | KCNA5 (0.42) | TSHRKMT2AMAPTATML3MBTL1 | |
| SCHEMBL16503517 | 0.85 | UGT2B7 (0.38) | TSHRMEN1KMT2AATML3MBTL1 | |
| SCHEMBL6525612 | 0.83 | ATM (0.39) | MEN1KMT2AMAPTATML3MBTL1 | |
| SCHEMBL16503514 | 0.83 | SMN1; SMN2 (0.37) | TSHRMEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL12600132 | 0.78 | OGA (0.36) | MEN1KMT2AALDH1A1 | |
| SCHEMBL16503526 | 0.77 | TSHR (0.47) | TSHRMEN1KMT2AMAPTHTT | |
| SCHEMBL14209810 | 0.76 | PPARA (0.36) | MEN1KMT2AATML3MBTL1ALDH1A1 | |
| SCHEMBL8405099 | 0.76 | GSR (0.44) | LMNAATML3MBTL1 | |
| SCHEMBL1739510 | 0.76 | GSR (0.44) | LMNAATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079869-B2 | Chiral disulfonimides | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2015-07-14 | — | — | US | disclosed |
| US-20110313150-A1 | CHIRAL DISULFONIMIDES | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313150-A1 | CHIRAL DISULFONIMIDES | STS, SUDS3, SF1 | TSHR 4279/4885MEN1 1578/4885KMT2A 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.